Trial Profile
Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Benzylguanine; Carmustine; Filgrastim; Plerixafor
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 29 Apr 2022 Status changed to discontinued.
- 27 May 2021 Status changed from active, no longer recruiting to completed.
- 31 Oct 2018 Planned primary completion date changed from 24 Mar 2018 to 24 Nov 2018.